Открытый доступ Открытый доступ  Закрытый доступ Доступ платный или только для подписчиков

Перспективы использования гранулоцит-макрофагального колониестимулирующего фактора в качестве иммуноадъюванта при вакцинопрофилактике (обзор)

Галина Михайловна Сысоева, Альбина Олеговна Белкина, Елена Дмитриевна Даниленко

Аннотация


Обзор посвящен рассмотрению результатов работ последних лет, касающихся изучения иммуноадъювантных эффектов гранулоцит-макрофагального колониестимулирующего фактора при вакцинации против инфекционных заболеваний, для усиления эффективности сконструированных вакцин на основе белковых антигенов, а также в качестве генетического адъюванта при ДНК-вакцинации.


Ключевые слова


гранулоцит-макрофагальный колониестимулирующий фактор, иммуномодулятор, адъювант, противовирусные вакцины

Ссылки


Warren T. L., Weiner G. J. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development / Curr. Opin. Hematol. 2000. V. 7. № 3. P. 168 – 173.

Белогурова М. Б. Клиническое использование гемопоэтических ростовых факторов / Практ. онкол. 2003. Т. 4. № 3. С. 183 – 190.

Мальцев Д. В. Показания к применению колониестимулирующих факторов в клинической практике / Клин. иммунол. аллергол. инфектол. 2018. Т. 106. № 1. C. 5 – 12.

Herrmann M., Zeiter S., Eberli U., Hildebrand M., Camenisch K., Menzel U., Alini M., Verrier S., Stadelmann V. A. Five Days Granulocyte Colony-Stimulating Factor Treatment Increases Bone Formation and Reduces Gap Size of a Rat Segmental Bone Defect: A Pilot Study / Front. Bioeng. Biotechnol. 2018. V. 12. № 6. P. 5.

Liu X. L., Rao N. J., Huo L., Hu X., Lu W. W., Zheng L. W. The influence of locally applied granulocyte-colony stimulating factor on osteoporotic bone / Clin. Oral Implants Res. 2017. V. 28. № 5. P. 586 – 593.

Hare J. M., Sanina C. Bone Marrow Mononuclear Cell Therapy and Granulocyte Colony-Stimulating Factor for Acute Myocardial Infarction: Is it Time to Reconsider? / J. Am. Coll. Cardiol. 2015. V. 65. № 22. P. 2383 – 2387.

Barrientos S., Brem H., Stojadinovic O., Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing / Wound Repair Regen. 2014. V. 22. № 5. P. 5695 – 5578.

Karlafti E., Savopoulos C., Hatzitolios A., Didangelos T. Lokal use of granulocyte-macropfage colony stimulating factor in treatment of chronic diabetic neuropathic ulcer (Case review) / Georgian Med. News. 2018. V. 277. P. 21 – 27.

Santos J. B., de Jesus A. R., Machado P. R., Magalhгes A., Salgado K., Carvalho E. M., Almeida R. P. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study / J. Infect. Dis. 2004. V. 190. № 10. P. 1793 – 1796.

Eftekhar M., Naghshineh E., Khani P. Role of granulocyte colony-stimulating factor in human reproduction / J. Res. Med. Sci. 2018. V. 23. № 7.

Vrtovec B., Haddad F., Pham M., Deuse T., Fearon W. F., Schrepfer S., Leon S., Vu T., Valantine H., Hunt S. A. Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients / Transplant. Proc. 2013. V. 45. № 6. P. 2406 – 2409.

Casciello N., Hulbert A., Snyder L., Byrns J. Incidence of acute cellular rejection following granulocyte colony-stimulating factor administration in lung transplantation: A retrospective case-cohort analysis / Clin. Transplant. 2017. V. 31. № 5.

McDonald J. U., Zhong Z., Groves H. T., Tregoning J. S. Inflammatory responses to influenza vaccination at the extremes of age / Immunology. 2017. V. 151. № 4. P. 451 – 463.

Rothchild A. C., Stowell B., Goyal G., Nunes-Alves C., Yang Q., Papavinasasundaram K., Sassetti C. M., Dranoff G., Chen X., Lee J., Behar S. M. Role of Granulocyte-Macrophage Colony-Stimulating Factor Production by T Cells during Mycobacterium tuberculosis Infection / MBio. 2017. V. 8. № 5.

Celmeli F., Oztoprak N., Turkkahraman D., Seyman D., Mutlu E., Frede N., Kцksoy S., Grimbacher B. Successful Granulocyte Colony-stimulating Factor Treatment of Relapsing Candida albicans Meningoencephalitis Caused by CARD9 Deficiency / Pediatr. Infect. Dis. J. 2016. V. 35. № 4. P. 428 – 431.

Gathwala G., Walia M., Bala H., Singh S. Recombinant human granulocyte colony-stimulating factor in preterm neonates with sepsis and relative neutropenia: a randomized, single-blind, non-placebo-controlled trial / J. Trop. Pediatr. 2012. V. 58. № 1. P. 12 – 18.

Akta? D., Demirel B., G?rsoy T., Oval F. A randomized case-controlled study of recombinant human granulocyte colony stimulating factor for the treatment of sepsis in preterm neutropenic infants / Pediatr. Neonatol. 2015. V. 56. № 3. P. 171 – 175.

Reed S. G., Orr M. T., Fox C. B. Key roles of adjuvants in modern vaccines / Nature Med. 2013. V. 19. P. 1597 – 1608.

Bowick G. C. and McAuley A. J. Vaccine and adjuvant design for emerging viruses. Mutations, deletions, segments and signaling / Bioeng. Bugs. 2011. V. 2. № 3. P. 129 – 135.

Исаенко Е. Ю., Бабич Е. М., Елисеева И. В., Ждамарова Л. А., Белозерский В. И., Колпак С. А. Адъюванты в современной вакцинологии / Ann. Mechnikov Instit. 2013. № 4. С. 3 – 21.

Yoon H. A., Aleyas A. G., George J. A., Park S. O., Han Y. W., Lee J. H., Cho J. G., Eo S. K. Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses / Microbiol. Immunol. 2006. V. 50. № 2. P. 83 – 92.

Robinson H. L., Montefiori D. C., Villinger F., Robinson J. E., Sharma S., Wyatt L. S., Earl P. L., McClure H. M., Moss B., Amara R. R. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine / Virology. 2006. V. 352. № 2. P. 285 – 294.

Lai L., Kwa S., Kozlowski P. A. Montefiori D. C., Ferrari G., Johnson W. E., Hirsch V., Villinger F., Chennareddi L., Earl P. L., Moss B., Amara R. R., Robinson H. L. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankarasimian immunodeficiency virus vaccine / J. Infect. Dis. 2011. V. 204. № 1. P. 164 – 173.

Wang X., Dong A., Xiao J., Zhou X., Mi H., Xu H., Zhang J., Wang B. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of ГМ-КСФ as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice / Cell. Mol. Immunol. 2016. V. 13. № 6. P. 850 – 861.

Li L., Petrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity / Expert. Rev. Vaccines. 2016. V. 15. № 3. P. 313 – 329.

Overton E. T., Kang M., Peters M. G., Umbleja T., Alston-Smith B. L., Bastow B., Demarco-Shaw D., Koziel M. J., Mong-Kryspin L., Sprenger H. L., Yu J. Y., Aberg J. A. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220 / Vaccine. 2010. V. 28. № 34. P. 5597 – 5604.

Overton E. T., Sungkanuparph S., Powderly W. G., Seyfried W., Groger R. K., Aberg J. A. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons / Clin. Infect. Dis. 2005. V. 41. P. 1045 – 1048.

Baylor N. W., Egan W., Richman P. Aluminum salts in vaccines-US perspective / Vaccine. 2002. V. 20. S18 - S23.

St?rkel P., Stoffel M., Lerut J., Horsmans Y. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients / Liver Transpl. 2005. V. 11. № 10. P. 1228 – 1234.

Zhao W., Zhou X., Zhao G., Lin Q., Wang X., Yu X., Wang B. Enrichment of Ly6Chi monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model / Hum. Vaccin. Immunother. 2017. V. 13. No. 12. P. 2872 – 2882.

Sasaki M. G., Foccacia R., de Messias-Reason I. J. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection / Vaccine. 2003. V. 21. P. 4545 – 4549.

Fabrizi F., Ganeshan S. V., Dixit V., Martin P. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease / Aliment. Pharmacol. Ther. 2006. V. 24. № 5. P. 789 – 796.

Chou H. Y., Lin X. Z., Pan W. Y., Wu P. Y., Chang C. M., Lin T. Y., Shen H. H., Tao M. H. Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the recruitment and activation of dendritic cells / J. Immunol. 2010. V. 185. № 9. P. 5468 – 5475.

Cruciani M., Mengoli C., Serpelloni G., Mazzi R., Bosco O., Malena M. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis / Vaccine. 2007. V. 25. № 4. P. 709 – 718.

Thio C. L., Seaberg E. C., Skolasky R. Jr., Phair J., Visscher B., Muсoz A., Thomas D. L. HIV-1, hepatitis B, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS) / Lancet. 2002. V. 360. № 9349. P. 1921 – 1926.

Grasse M., Meryk A., Miggitsch C., Grubeck-Loebenstein B. GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine / Vaccine. 2018. V. 36. No. 31. P. 4672 – 4680.

Zhang C., Wang B., Wang M. GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease / Virol. J. 2011. V. 8. P. 7. doi: 10.1186/1743-422X-8-7.

Sun Z., Liang J., Dong X., Wang C., Kong D., Lv F. Injectable Hydrogels Coencapsulating Granulocyte-Macrophage Colony-Stimulating Factor and Ovalbumin Nanoparticles to Enhance Antigen Uptake Efficiency / ACS Appl. Mater. Interfac. 2018. V. 10. № 24. P. 20315 – 20325.

Babai I., Barenholz Y., Zakay-Rones Z., Greenbaum E., Samira S., Hayon I., Rochman M., Kedar E. A novel liposomal influenza vaccine (INFLU¬SOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains / Vaccine. 2001. V. 20. № 3 – 4. P. 505 – 515.

Littauer E. Q., Mills L. K., Brock N., Esser E. S., Romanyuk A., Pulit-Penaloza J. A., Vassilieva E. V., Beaver J. T., Antao O., Krammer F., Compans R. W., Prausnitz M. R., Skountzou I. Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza / J. Control Rel. 2018. V. 276. P. 1 – 16.

Li L., Saade F., Petrovsky N. The future of human DNA vaccines / J. Biotechnol. 2012. V. 162. № 2 – 3. P. 171 – 182.

Khan K. H. DNA vaccines: roles against diseases / Germs. 2013. V. 3. № 1. P. 26 – 35.

Yang B., Jeang J., Yang A., Wu T. C., Hung C. F. DNA vaccine for cancer immunotherapy / Hum. Vaccin. Immunother. 2014. V. 10. № 11. P. 3153 – 3164.

Савилова А. М., Трофимов Д. Ю., Алексеев Л. П., Хаитов Р. М. ДНК-вакцины: современное состояние и перспективы / Иммунология. 2007. № 2. C. 114 – 123.

Xu R., Megati S., Roopchand V., Luckay A., Masood A., Garcia-Hand D., Rosati M., Weiner D. B., Felber B. K., Pavlakis G. N., Sidhu M. K., Eldridge J. H., Egan M. A. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines / Vaccine. 2008. V. 26. № 37. P. 4819 – 4829.

Yu T. W., Chueh H. Y., Tsai C. C., Lin C. T., Qiu J. T. Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines / Hum. Vaccin. Immunother. 2016. V. 12. № 12. P. 3020 – 3028.

Козлов А. Ю., Климова P. P., Шингарова Л. Н. Болдырева Е. Ф., Некрасова О. В., Гурьянова С. В., Андронова Т. М., Новиков В. В., Кущ А. А. Сравнительный анализ адъювантных свойств глюкозаминилмурамилдипептида и гена гранулоцитарно-макрофагального колониестимулирующего фактора при ДНК-иммунизации против вируса простого герпеса / Мол. биол. 2005. № 3. С. 504 – 512.

Qing Y., Chen M., Zhao J., Hu H., Xu H., Ling N., Peng M., Ren H. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice / Vaccine. 2010. V. 28. № 26. P. 4301 – 4307.

Hartoonian C., Ebtekar M., Soleimanjahi H., Karami A., Mahdavi M., Rastgoo N., Azadmanesh K. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine / Cytokine. 2009. V. 46. № 1. P. 43 – 50.

Mahdavi M., Tajik A. H., Ebtekar M., Rahimi R., Adibzadeh M. M., Moozarmpour H. R., Beikverdi M. S., Olfat S., Hassan Z. M., Choopani M., Kameli M., Hartoonian C. Granulocyte-macrophage colony-stimulating factor, a potent adjuvant for polarization to Th-17 pattern: an experience on HIV-1 vaccine model / APMIS. 2017. V. 125. № 6. P. 596 – 603.

Qiu J. T., Chang T. C., Lin C. T., Chen Y. M., Li F. Q., Soong Y. K., Lai C. H. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag / Vaccine. 2007. V. 25. № 2. P. 253 – 263.

Lai L., V?dr?s D., Kozlowski P. A., Montefiori D. C., Wilson R. L., Akerstrom V. L., Chennareddi L., Yu T., Kannanganat S., Ofielu L., Villinger F., Wyatt L. S., Moss B., Amara R. R., Robinson H. L. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA / MVA immunodeficiency virus vaccine / Virology. 2007. V. 369. № 1. P. 153 – 167.

Liu W. C., Liu Y. Y., Chen T. H., Liu C. C., Jan J. T., Wu S. C. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design / Antivir. Res. 2016. V. 133. P. 110 – 118.

Lee H. J., Hur Y. K., Cho Y. D., Kim M. G., Lee H. T., Oh Y. K., Kim Y. B. Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs / PloS One. 2012. V. 7. № 11. e50296.

Cho H., Lee H. J., Heo Y. K., Cho Y., Gwon Y. D., Kim M. G., Park K. H., Oh Y. K., Kim Y. B. Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine / PloS One. 2014. V. 9. № 4. e95961.

Choi H. J., Gwon Y. D., Jang Y., Cho Y., Heo Y. K., Lee H. J., Kim K. C., Choi J., Lee J. B., Kim Y. B. Effect of AcHERV-GmCSF as an Influenza Virus Vaccine Adjuvan / PLoS One. 2015. V. 10. № 6. e0129761.

Loudon P. T., Yager E. J., Lynch D. T., Narendran A., Stagnar C., Franchini A. M., Fuller J. T., White P. A., Nyuandi J., Wiley C. A., Murphey-Corb M., Ful¬ler D. H. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates / PLoS One. 2010. V. 5. № 6. e11021.

Suschak J. J., Bagley K., Shoemaker C. J., Six C., Kwilas S., Dupuy L. C., Schmaljohn C. S. The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice / J. Infect. Dis. 2018. 218(suppl 5). S519-S527.

Lu H., Xu X. F., Gao N., Fan D. Y., Wang J., An J. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM / E and NS1: Their immunity and protective efficacy in mice / Mol. Immunol. 2012. V. 54. № 2. P. 109 – 114.

Zheng Q., Fan D., Gao N., Chen H., Wang J., Ming Y., Li J., An J. Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection / Vaccine. 2011. V. 29. № 4. P. 763 – 771.

Bharati K., Appaiahgari M. B., Vrati S. Effect of cytokine-encoding plasmid delivery on immune response to Japanese encephalitis virus DNA vaccine in mice / Microbiol. Immunol. 2005. V. 49. № 4. P. 349 – 353.

Zhai Y. Z., Li X. M., Zhou Y., Ma L., Feng G. H. Intramuscular immunization with a plasmid DNA vaccine encoding prM-E protein from Japanese encephalitis virus: enhanced immunogenicity by co-administration of ГМ-КСФ gene and genetic fusions of prM-E protein and GM-CSF / Intervirology. 2009. V. 52. № 3. P. 152 – 163.

Zhai Y., Zhou Y., Li X., Feng G. Immune-enhancing effect of nano-DNA vaccine encoding a gene of the prME protein of Japanese encephalitis virus and BALB / c mouse granulocyte-macrophage colony-stimulating factor / Mol. Med. Rep. 2015. V. 12. № 1. P. 199 – 209.

Wu J. M., Chen H., Sheng Z. Y., Wang J., Fan D. Y., Gao N., An J. [The adjuvant effect of granulocyte macrophage colony stimulating factor (GM-CSF) in dengue virus and hepatitis C virus DNA vaccines] / Bing Du Xue Bao. 2012. V. 28. № 3. P. 207 – 212. [Article in Chinese].

Gao N., Chen W., Zheng Q., Fan D. Y., Zhang J. L., Chen H., Gao G. F., Zhou D. S., An J. Co-expression of Japanese encephalitis virus prM-E-NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination / Immunol. Lett. 2010. V. 129. № 1. P. 23 – 31.

Chen H., Gao N., Fan D., Wu J., Zhu J., Li J., Wang J., Chen Y., An J. Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-¬CSF-expressing plasmid in mice / PLoS One. 2012. V. 7. № 4. e34602.

Chen H., Gao N., Wu J., Zheng X., Li J., Fan D., An J. Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice / Immunol. Lett. 2014. V. 162. № 1. Pt A. P. 140 – 148.

Haddad D., Ramprakash J., Sedegah M., Charoenvit Y., Baumgartner R., Kumar S., Hoffman S. L., Weiss W. R. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles / J. Immunol. 2000. V. 165. № 7. P. 3772 – 3781.

Peng X., Fang X., Li J., Kong L., Li B., Ding X. Enhancing immune responses of EV71 VP1 DNA vaccine by co-inoculating plasmid IL-12 or GM-CSF expressing vector in mice / Cell. Mol. Biol. (Noisy-le-grand). 2016. V. 62. № 4. P. 35 – 41.

Tan B., Wang H., Shang L., Yang T. Coadministration of chicken GM-CSF with a DNA vaccine expressing infectious bronchitis virus (IBV) S1 glycoprotein enhances the specific immune response and protects against IBV infection / Arch. Virol. 2009. V. 154. № 7. P. 1117 – 1124.

Zhou M., Zhang G., Ren G., Gnanadurai C. W., Li Z., Chai Q., Yang Y., Leyson C. M., Wu W., Cui M., Fu Z. F. Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations / PLoS One. 2013. V. 8. № 5. e63384.

Zhou M., Wang L., Zhou S., Wang Z., Ruan J., Tang L., Jia Z., Cui M., Zhao L., Fu Z. F. Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs / Oncotarget. 2015. V. 6. № 36. P. 38504 – 38516.


Полный текст: PDF

Ссылки

  • Ссылки не определены.


** ** ** ** ** **

ISSN: 2073-8099

** ** ** ** ** **

 

Подписаться на наши издания Вы можете через почтовые каталоги агентства «Роспечать» и Объединенный каталог «Пресса России», а также на сайтах агентств «УП Урал Пресс», «Прессинформ» и «Профиздат».